Table 4.
Characteristics of People Living With Human Immunodeficiency Virus Initiating Antiretroviral Therapy (ART) of ≥45 Days’ Duration and With an Available Weight Measure at 12 Months (±6 Months) After ART Initiation Date, 2007–2016, in Participating North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) Cohorts (Those With ≥50 Individuals Receiving Each Active Agent), Stratified by Active Agent of Regimen Core
| Characteristic | Total No. | NNRTI-Based (n = 7559) |
PI-Based (n = 3961) |
RAL-Based (n = 812) |
DTG-Based (n = 758) |
EVG-Based (n = 1623) |
Combined (N = 14 713) |
Interagent P Value |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex assigned at birth | 14 713 | <.001a | ||||||||||||
| Male | 0.91 | (6911) | 0.83 | (3276) | 0.84 | (685) | 0.85 | (644) | 0.88 | (1436) | 0.88 | (12 952) | ||
| Female | 0.09 | (648) | 0.17 | (685) | 0.16 | (127) | 0.15 | (114) | 0.12 | (187) | 0.12 | (1761) | ||
| Race/ethnicity | 14 239 | .004a | ||||||||||||
| White, non-Hispanic | 0.40 | (2891) | 0.38 | (1461) | 0.45 | (353) | 0.38 | (284) | 0.37 | (589) | 0.39 | (5578) | ||
| Non-white | 0.60 | (4400) | 0.62 | (2358) | 0.55 | (438) | 0.62 | (462) | 0.63 | (1003) | 0.61 | (8661) | ||
| HIV transmission risk | 14 713 | <.001a | ||||||||||||
| MSM | 0.39 | (2921) | 0.36 | (1432) | 0.42 | (345) | 0.61 | (464) | 0.61 | (992) | 0.42 | (6154) | ||
| IDU, including MSM/IDU | 0.12 | (921) | 0.16 | (635) | 0.12 | (97) | 0.05 | (39) | 0.07 | (114) | 0.12 | (1806) | ||
| Heterosexual | 0.13 | (998) | 0.21 | (830) | 0.18 | (149) | 0.24 | (179) | 0.19 | (311) | 0.17 | (2467) | ||
| Other/unknown | 0.36 | (2719) | 0.27 | (1064) | 0.27 | (221) | 0.10 | (76) | 0.13 | (206) | 0.29 | (4286) | ||
| Ageb, y | 14 713 | 43 (32, 51) | 42 (32, 51) | 44 (34, 52) | 36 (28, 49) | 34 (27, 46) | 42 (31, 51) | <.001c | ||||||
| Baseline weightb, kg | 13 054 | 78 (69, 89) | 77 (68, 88) | 78 (68, 90) | 76 (67, 88) | 77 (67, 90) | 78 (68, 89) | <.001c | ||||||
| Weight at 1 y after ARTb, kg | 14 713 | 80 (70, 91) | 80 (70, 92) | 81 (72, 94) | 79 (70, 93) | 80 (69, 93) | 80 (70, 92) | .093c | ||||||
| Baseline BMIb, kg/m2 | 12 635 | 25 (23, 28) | 25 (22, 28) | 26 (23, 29) | 25 (22, 29) | 25 (22, 29) | 25 (22, 28) | .022c | ||||||
| Baseline CD4+ countb, cells/µL | 12 943 | 320 (190, 462) | 268 (110, 417) | 339 (162, 505) | 402 (207, 592) | 385 (220, 557) | 317 (170, 473) | <.001c | ||||||
| Baseline log10 HIV-1 RNAb | 12 286 | 4.6 (4.0, 5.0) | 4.7 (4.1, 5.2) | 4.6 (4.0, 5.1) | 4.6 (4.1, 5.1) | 4.6 (4.1, 5.1) | 4.6 (4.0, 5.1) | <.001c | ||||||
| Year of ART initiationb | 14 713 | 2010 (2008, 2012) | 2010 (2008, 2012) | 2011 (2010, 2012) | 2015 (2015, 2016) | 2014 (2014, 2015) | 2011 (2009, 2013) | <.001c | ||||||
| Incident diabetes mellitus | 14 713 | <.001a | ||||||||||||
| No | 0.97 | (7364) | 0.98 | (3875) | 0.97 | (789) | 1.00 | (755) | 0.99 | (1603) | 0.98 | (14 386) | ||
| Yes | 0.03 | (195) | 0.02 | (86) | 0.03 | (23) | 0.00 | (3) | 0.01 | (20) | 0.02 | (327) | ||
| Follow-up timeb, y | 14 713 | 2.29 (0.71, 4.38) | 1.45 (0.24, 3.64) | 1.78 (0.54, 3.74) | 0.57 (0.16, 1.22) | 1.03 (0.30, 2.02) | 1.71 (0.42, 3.74) | <.001c |
Numbers in parentheses after proportions are frequencies. N is the number of nonmissing values.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; DTG, dolutegravir; EVG, elvitegravir; HIV, human immunodeficiency virus; HIV-1, human immunodeficiency virus type 1; IDU, injection drug use; MSM, men who have sex with men; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; RAL, raltegravir.
aPearson χ 2 test.
bMedian (lower quartile, upper quartile).
cKruskal-Wallis test.